Objective: To investigate the expressions of Pax-5 and miR-215 in epithelial ovarian cancer tissues and their relationships with prognosis. Methods: 80 cases of epithelial ovarian cancer tissues and normal epithelial tissues were collected, the expression levels of Pax-5 and miR-215 in tissues were detected by real-time fluorescence quantitative PCR (RT-PCR). Pearson correlation coefficient (r) method was used to analyze the correlation between Pax-5 and microRNA-215 in epithelial ovarian cancer and their relationships with clinicopathological characteristics. Kaplan-Meier (K-M) survival curve was used to analyze the effect of Pax-5 and miR-215 expression levels on the tumor-free survival rate of patients. COX regression model was used to analyze the risk factors affecting the tumor-free survival of epithelial ovarian cancer. Results: The expression levels of Pax-5 and miR-215 in epithelial ovarian cancer tissues were lower than those in normal ovarian epithelial tissues (1.39±0.36) vs(2.03±0.54),(0.92±0.27) vs (1.36±0.41), the difference was significant (P<0.05); Pax-5 and miR-215 were positively correlated in epithelial ovarian cancer(r=0.677, P=0.010); the expression of Pax-5 was correlated with lymph node metastasis(1.30±0.29) vs (1.53±0.33), tumor size (1.32±0.25) vs (1.46±0.31) and postoperative recurrence (1.29±0.18) vs (1.44±0.32) in epithelial ovarian cancer (P<0.05), the expressions of miR-215 was correlated with FIGO stage (0.97±0.20) vs (0.85±0.23), lymph node metastasis (0.83±0.19) vs (1.06±0.24), tumor size (0.86±0.20) vs (0.97±0.21) and postoperative recurrence(0.79±0.18) vs (0.98±0.23) (P<0.05); the tumor-free survival rate of patients with higher expression of Pax-5 was higher than those with lower expression of Pax-5 (P<0.05), the tumor-free survival rate of patients with higher expression of miR-215 was higher than those of lower expression of miR-215 (P<0.05); lymph node metastasis, tumor size, postoperative recurrence and the expressions of Pax-5 and miR-215 were independent risk factors for postoperative tumor-free survival after epithelial ovarian cancer surgery (OR=3.792, 3.309, 4.276, 2.692, 2.090, P<0.05). Conclusion: The expressions of Pax-5 and miR-215 are down-regulated in epithelial ovarian cancer tissue, which is related to malignant behaviors such as proliferation, metastasis and poor prognosis of epithelial ovarian cancer.
 NUTT S L,HEAVEY B,ROLINK A G,et al.Commitment to the B-lymphoid lineage depends on the transcription factor Pax5[J].Nature,2015,401(6753):556-562.
 BENZINA S,HARQUAIL J,GUERRETTE R,et al.Breast cancer malignant processes are regulated by Pax-5 through the disruption of FAK signaling pathways[J].J Cancer,2016,7(14):2035-2044.
 HARQUAIL J,LEBLANC N,LANDRY C,et al.Pax-5,inhibits NF-κB activity in breast cancer cells through IKKε and miRNA-155 effectors[J].J Mammary Gland Biol Neoplasia,2018,23(3):177-187.
 YANG L,YANG J,XU T,et al.microRNA-215 targets NOB1 and inhibits growth and invasion of epithelial ovarian cancer[J].Am J Transl Res,2017,9(2):466-477.
 ZEPPERNICK F,MEINHOLD-HEERLEIN I.The new FIGO staging system for ovarian,fallopian tube,and primary peritoneal cancer[J].Arch Gynecol Obstet,2014,290(5):839-842.
 ARUN I,ROY P,ARORA N,et al.PAX-5 Positivity in anaplastic lymphoma kinase-negative anaplastic large cell lymphoma[J].Int J Surg Pathol,2016,25(4):333-338.
 BENZINA S,BEAUREGARD A P,GUERRETTE R,et al.Pax-5 is a potent regulator of E-cadherin and breast cancer malignant processes[J].Oncotarget,2017,8(7):12052-12066.
 BRACKEN C P,SCOTT H S,GOODALL G J.A network-biology perspective of microRNA function and dysfunction in cancer[J].Nat Rev Genet,2016,17(12):719-732.
 GE G,ZHANG W,NIU L,et al.miR-215 functions as a tumor suppressor in epithelial ovarian cancer through regulation of the X-chromosome-linked inhibitor of apoptosis[J].Oncol Rep,2015,35(3):1816-1822.
 LEBLANC N,HARQUAIL J,CRAPOULET N,et al.Pax-5 inhibits breast cancer proliferation through miR-215 up-regulation[J].Anticancer Res,2018,38(1):5013-5026